66. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: A clinical perspective. Endocrine Rev 2001; 22:36-52.

67. Zeng G, Nystrom FH, Ravichandran LV, Cong L-N, Kirby M, Mostowski H, Quon MJ. Roles for insulin receptor, PI 3-kinase, and Akt in insulin-signaling pathways related to production of nitris oxide in human vascular endothelial cells. Circulation 2000; 101:1539-1545.

68. Thomas GD, Ahang W, Victor RG. Nitric oxide deficiency as a cause of clinical hypertension: Promising new drug targets for refractory hypertension. JAMA 2001; 285:2055-2057.

69. Tooke JE. Endotheliopathy precedes type 2 diabetes. Diabetes Care 1998; 21:20472049.

70. Yudkin JS, Panahloo A, Stehouwer C, Emeis JJ, Bulmer K, Mohamed-Ali V, Denver AE. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II Diabetic subjects. Diabetologia 2000; 43:1099-1106.

71. Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? Diabetes Care 1999; 22(suppl 3):C25-C30.

72. Carr ME. Diabetes mellitus: A hypercoagulable state. J Diabetes Complications 2001; 15:44-54.

73. Meigs JBJ, Mittleman MA, Nthan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D'Agostino RB, Wilson PWF. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: The Framingham Offspring Study. JAMA 2000; 283:221-228.

74. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999; 282:2131-2135.

75. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102:42-47.

76. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int 2000; 58:1703-1710.

77. Feingold KR, Grunfeld C, Pang M, Doerrier W, Krauss RM. LDL subclass pheno-types and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 1992; 12:1496-1502.

78. Festa A, D'Agostino R Jr, Mykkanen L, Tracy RP, Hales CN, Howard BV, Haffner SM. LDL particle size in relation to insulin, proinsulin, and insulin sensitivity. Diabetes Care 1999; 22:1688-1693.

79. Ginsberg HN, Tuck C. Diabetes and dyslipidemia. In: Lebovitz HE, ed. Educational Review Manual in Endocrinology and Metabolism. New York: Castle Connolly Graduate Medical Publishing, 2000:1-47.

80. Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: The Insulin Resistance Atherosclerosis Study. Diabetes 1998; 47:793-800.

81. Wagenknecht LE, D'Agostino RB Jr, Haffner SM Savage PJ, Rewers M. Impaired glucose tolerance, type 2 diabetes, and carotid wall thickness: The Insulin Resistance

Atherosclerosis Study. Diabetes Care 1998; 21:1812-1818. f

82. Laakso M, Ronnemaa T, Lehto S, Puukka P, Kallio V, Pyoräla K. Does NIDDM

Diabetes 2

Diabetes 2

Diabetes is a disease that affects the way your body uses food. Normally, your body converts sugars, starches and other foods into a form of sugar called glucose. Your body uses glucose for fuel. The cells receive the glucose through the bloodstream. They then use insulin a hormone made by the pancreas to absorb the glucose, convert it into energy, and either use it or store it for later use. Learn more...

Get My Free Ebook

Post a comment